837 results match your criteria American Journal Of Cardiovascular Drugs[Journal]


Effects of Statins to Reduce All-Cause Mortality in Heart Failure Patients: Findings from the EPICAL2 Cohort Study.

Am J Cardiovasc Drugs 2019 Apr 10. Epub 2019 Apr 10.

CHRU Nancy, Université de Lorraine, Plateforme d'Aide à la Recherche Clinique, 54000, Nancy, France.

Introduction: The addition of statins to standard care in heart failure (HF) patients remains controversial in clinical practice. Large-scale clinical trials failed to show mortality benefits, but uncertainty persists in real-world settings.

Objective: We evaluated whether the prescription of statins at hospital discharge is associated with a reduction in all-cause mortality at up to 1 year of follow-up in HF patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40256-019-00346-4
Publisher Site
http://dx.doi.org/10.1007/s40256-019-00346-4DOI Listing
April 2019
1 Read

Adenosine and the Cardiovascular System.

Am J Cardiovasc Drugs 2019 Apr 10. Epub 2019 Apr 10.

Department of Medicine and Winthrop Research Institute, NYU Winthrop Hospital, 101 Mineola Boulevard, Mineola, NY, 11501, USA.

Adenosine is an endogenous nucleoside with a short half-life that regulates many physiological functions involving the heart and cardiovascular system. Among the cardioprotective properties of adenosine are its ability to improve cholesterol homeostasis, impact platelet aggregation and inhibit the inflammatory response. Through modulation of forward and reverse cholesterol transport pathways, adenosine can improve cholesterol balance and thereby protect macrophages from lipid overload and foam cell transformation. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40256-019-00345-5
Publisher Site
http://dx.doi.org/10.1007/s40256-019-00345-5DOI Listing
April 2019
2 Reads

Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization.

Am J Cardiovasc Drugs 2019 Apr 3. Epub 2019 Apr 3.

International Heart Institute, Loma Linda University Medical Center, 11234 Anderson Street, Suite 2426, Loma Linda, CA, 92354, USA.

Direct oral anticoagulants (DOACs) have been developed as a viable and in some cases superior alternative to warfarin. These agents have overcome some of the limitations of warfarin, which has a narrow therapeutic window and many food and drug interactions. DOACs have been demonstrated to have a more predictable and reliable pharmacology and, unlike warfarin, do not require frequent monitoring of anticoagulant effect. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40256-019-00344-6
Publisher Site
http://dx.doi.org/10.1007/s40256-019-00344-6DOI Listing
April 2019
8 Reads

Novel Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation and Hypertension: A Meta-Analysis.

Am J Cardiovasc Drugs 2019 Apr 1. Epub 2019 Apr 1.

Laboratory of Physiological Sciences, Guangdong Medical University, 2 Renmindong Road, Zhanjiang, 524023, Guangdong, People's Republic of China.

Introduction: Hypertension is associated with increased risk of stroke and bleeding in patients with atrial fibrillation (AF). In the present study, we aimed to investigate the influence of hypertension status in patients with AF receiving treatment with non-vitamin K antagonist oral anticoagulants (NOACs).

Methods: PubMed, Embase, and Cochrane Library were searched from the inception of each database to November 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00342-8DOI Listing
April 2019
2 Reads

Renin-Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study.

Am J Cardiovasc Drugs 2019 Mar 28. Epub 2019 Mar 28.

Cardiology Department, University Hospital Álvaro Cunqueiro, Estrada Clara Campoamor, 341, 36212, Vigo, Pontevedra, Spain.

Introduction: The goal of this study was to determine the association between the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and follow-up heart failure (HF) according to left ventricular ejection fraction (LVEF) in patients with acute myocardial infarction (AMI).

Methods: This cohort study used a retrospective registry of 8169 consecutive patients discharged with a diagnosis of AMI from two university hospitals in Spain between 2010 and 2016. We used a multivariable competing risk analysis, survival-time inverse probability weighting (IPW) propensity score adjusting, and propensity score matching (PSM) to investigate the association between ACEI/ARB treatment and follow-up HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00343-7DOI Listing

Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension.

Am J Cardiovasc Drugs 2019 Mar 28. Epub 2019 Mar 28.

NHLI, Imperial College London, London, UK.

Background: Angiotensin-converting enzyme inhibitors and calcium channel blockers in combination are widely recommended in hypertension guidelines. The advantages of single-pill combinations (SPCs) are increasingly recognized, so a dosage-adapted combination of perindopril and amlodipine was developed for the initial management of hypertension.

Objective: This randomized trial evaluated the blood pressure (BP)-lowering efficacy of four incremental doses of perindopril/amlodipine SPC in adults with mild-to-severe hypertension. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00314-4DOI Listing

Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study.

Am J Cardiovasc Drugs 2019 Mar 6. Epub 2019 Mar 6.

Chair of Cardiology, University of the Study of Campania "Luigi Vanvitelli"-Monaldi Hospital, Naples, Italy.

Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events.

Objectives: This study compared the long-term efficacy and safety of apixaban with that of uninterrupted vitamin K antagonist (VKA) therapy in patients with AF scheduled for transesophageal echocardiogram (TEE)-guided direct current cardioversion (DCC) from June 2014 to September 2016.

Methods: We enrolled consecutive patients with persistent nonvalvular AF scheduled to undergo DCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00341-9DOI Listing
March 2019
2 Reads

Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.

Am J Cardiovasc Drugs 2019 Mar 4. Epub 2019 Mar 4.

Division of Cardiology, Cook County Health and Hospitals System, Chicago, IL, USA.

Background: The newer P2Y inhibitors have better efficacy than clopidogrel. However, whether ticagrelor or prasugrel have a better comparative safety and efficacy profile, especially in the long-term, remains inconclusive.

Objective: We compared prasugrel and ticagrelor in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40256-019-00337-5
Publisher Site
http://dx.doi.org/10.1007/s40256-019-00337-5DOI Listing
March 2019
8 Reads
2.203 Impact Factor

Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction?

Am J Cardiovasc Drugs 2019 Mar 4. Epub 2019 Mar 4.

Sorbonne Université, ACTION Study Group, APHP, INSERM, UMRS 1166, Hôpital Pitié-Salpêtrière, Institut de Cardiologie- Bureau 7-2ème étage, 47-83 bld de l'Hôpital, 75013, Paris, France.

The lifelong use of β-adrenoceptor antagonists (β-blockers) after a myocardial infarction (MI) has been the standard of care based on trials performed before the era of revascularization, when heart failure was common. Large randomized trials in the mid-1980s demonstrated that β-blockers played a major role in improving the in-hospital and long-term survival of patients admitted for MI. However, the implementation of rapid myocardial reperfusion led to a substantial survival benefit and a reduction of heart failure because of reduced infarct size. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00338-4DOI Listing
March 2019
5 Reads
2.203 Impact Factor

Correction to: FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.

Am J Cardiovasc Drugs 2019 04;19(2):227

Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Room #4128, Silver Spring, MD, USA.

The author name that previously read. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00335-7DOI Listing
April 2019
6 Reads

Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs.

Am J Cardiovasc Drugs 2019 Feb 27. Epub 2019 Feb 27.

The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive, Rensselaer, NY, 12144, USA.

While substantial evidence supports the use of standard-duration injectable anticoagulants for venous thromboembolism (VTE) prophylaxis, consensus is mixed about which agents may be preferred in acutely ill patients with ongoing need of VTE prophylaxis past the first 10-day duration of hospital stay and post-discharge. Non-vitamin K antagonist oral anticoagulants (NOACs) provide Factor Xa inhibition to prevent the thrombin generation essential in thromboembolism development, but evidence for the efficacy and safety of most NOACs is conflicting regarding extended-duration prophylaxis. Enoxaparin, a preferred injectable anticoagulant in standard-duration VTE prophylaxis, has shown an increased risk of major bleeding events when used in extended-duration prophylaxis, which outweighs its benefit. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40256-019-00329-5
Publisher Site
http://dx.doi.org/10.1007/s40256-019-00329-5DOI Listing
February 2019
5 Reads

Pharmacoinvasive Approach with Streptokinase in Low to Intermediate Risk ST-Elevation Myocardial Infarction Patients: Insights from the Tamil Nadu-STEMI Initiative.

Am J Cardiovasc Drugs 2019 Feb 23. Epub 2019 Feb 23.

Madras Medical Mission Hospital, 4-A, Dr. J. Jayalalitha Nagar, Mogappair, Chennai, Tamilnadu, 600037, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00327-7DOI Listing
February 2019

Pharmacotherapy of Obesity: Limits and Perspectives.

Am J Cardiovasc Drugs 2019 Feb 22. Epub 2019 Feb 22.

Departamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373, CCS-Bloco A, 2º andar, sala 48, Cidade Universitária, Rio de Janeiro, RJ, CEP 21941-902, Brazil.

Obesity is a severe worldwide epidemic. Obesity comorbidities, such as type 2 diabetes mellitus, hypertension, and atherosclerosis, are costly for patients and governments. The treatment of obesity involves several facets, including lifestyle changes, bariatric surgery, and pharmacotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00328-6DOI Listing
February 2019

Evidence-Based Cardiovascular Risk Management in Diabetes.

Am J Cardiovasc Drugs 2019 Feb 22. Epub 2019 Feb 22.

Department of Medicine, University of Florida College of Medicine, 653-1 West 8th Street, 4th Floor-LRC, Jacksonville, FL, 32209, USA.

Multipronged risk management in diabetes has contributed to the recent decline in cardiovascular mortality. Few antihyperglycemic drugs have been conclusively shown to have cardioprotective effects. These include metformin, liraglutide, semaglutide, dulaglutide, and sodium-glucose cotransporter-2 inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00336-6DOI Listing
February 2019
1 Read

Comment on: "Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials".

Am J Cardiovasc Drugs 2019 Apr;19(2):219-221

Boehringer Ingelheim India Pvt. Ltd, 400051, Mumbai, Maharashtra, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00333-9DOI Listing

Authors' Reply to Rana et al. "Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials".

Am J Cardiovasc Drugs 2019 Apr;19(2):223-224

K.G. Hospital and Post Graduate Institute, Coimbatore, Tamil Nadu, 641018, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00334-8DOI Listing
April 2019
1 Read

Effects of Rosuvastatin and Aspirin on Retinal Vascular Structures in Hypercholesterolemic Patients with Low-to-Moderate Risk of Coronary Artery Disease.

Am J Cardiovasc Drugs 2019 Feb 22. Epub 2019 Feb 22.

Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, No.1, Dong Jiao Min Xiang, Dong Cheng District, Beijing, 100730, China.

Introduction: Atherosclerosis erodes large elastic arteries and damages peripheral small vessels. Evaluating retinal vessel caliber enables exploration of the effect of improving microcirculation with statins.

Objective: We investigated whether rosuvastatin therapy improves retinal vasculature in hypercholesterolemic patients with a low-to-moderate risk of coronary artery disease (CAD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00330-yDOI Listing
February 2019
2 Reads
2.203 Impact Factor

Clinical Outcomes at 2 Years Between Beta-Blockade with ACE Inhibitors or ARBs in Patients with AMI Who Underwent Successful PCI with DES: A Retrospective Analysis of 23,978 Patients in the Korea AMI Registry.

Am J Cardiovasc Drugs 2019 Feb 20. Epub 2019 Feb 20.

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Introduction: Data concerning the clinical impact of combination therapy with β-blockers (BBs) + angiotensin-converting enzyme inhibitors (ACEIs) compared with BBs + angiotensin-receptor blockers (ARBs) in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) are limited.

Objective: We compared the clinical outcomes at 2 years between these two combination therapies.

Methods: We enrolled 23,978 patients with AMI who underwent successful PCI with DES between January 2005 and June 2015 from the Korea AMI Registry (KAMIR) and divided them into the two groups: BB + ACEI (n = 17,310) and BB + ARB (n = 6668). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00326-8DOI Listing
February 2019
1 Read
2.203 Impact Factor

The Efficacy and Safety of Aerosolized Iloprost in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.

Am J Cardiovasc Drugs 2019 Feb 19. Epub 2019 Feb 19.

Department of Cardiology, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China.

Background: This systematic review and meta-analysis was conducted to investigate the efficacy and safety of the chronic administration of aerosolized iloprost for pulmonary arterial hypertension (PAH).

Methods: All the relevant studies were obtained from three databases, namely, PubMed, Web of Science and the Cochrane Library, from the inception of each database to June 1, 2018. In our study, chronic treatment was defined as a period lasting at least 3 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00324-2DOI Listing
February 2019
1 Read

Cardiovascular Protection with Anti-hyperglycemic Agents.

Am J Cardiovasc Drugs 2019 Feb 15. Epub 2019 Feb 15.

Division of Cardiology, Department of Medicine, Sarver Heart Center, University of Arizona College of Medicine, Tucson, AZ, 85724-5037, USA.

Diabetes mellitus is a major risk factor for cardiovascular (CV) disease. Conversely, CV disease is responsible for a majority of the deaths in patients with diabetes. Many drug trials have concentrated on blood glucose (hemoglobin A) reduction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00325-9DOI Listing
February 2019
7 Reads

Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction.

Am J Cardiovasc Drugs 2019 Feb 12. Epub 2019 Feb 12.

Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123, Ta Pei Road, Niao-Sung District, Kaohsiung, 83301, Taiwan.

Objective: This study investigated the efficacy and safety of ticagrelor compared with clopidogrel in patients with end-stage renal disease (ESRD) and acute myocardial infarction (AMI).

Methods: We retrospectively enrolled patients who had received regular dialysis and had undergone percutaneous coronary intervention (PCI) for AMI at our hospital between January 2013 and December 2016. Outcomes analyzed included cardiovascular death, death from any cause, MI, stroke, and bleeding events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00318-0DOI Listing
February 2019
2 Reads

Correction to: Plasma Vitamin K Levels in Italian Patients Receiving Oral Anticoagulant Therapy for Mechanical Heart Prosthesis: A Case-Control Study.

Am J Cardiovasc Drugs 2019 04;19(2):225

Department of Chemistry, "Sapienza" Università, Rome, Italy.

Throughout the manuscript the units of plasma vitamin K1 concentration which previously read. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-019-00331-xDOI Listing

Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.

Am J Cardiovasc Drugs 2019 Feb 9. Epub 2019 Feb 9.

Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, China.

Introduction: Current guidelines recommend renin-angiotensin-aldosterone system (RAAS) inhibitors in the treatment of diabetic kidney disease (DKD). However, evidence suggests that the combined use of RAAS blockers may be associated with increased rates of adverse events.

Objectives: Our objective was to examine the efficacy and safety of dual blockade of the RAAS in patients with DKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00321-5DOI Listing
February 2019
2 Reads

Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination.

Am J Cardiovasc Drugs 2019 Feb 4. Epub 2019 Feb 4.

Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, 100 Science Road, Zhengzhou, 450001, China.

Elevated serum low-density lipoprotein cholesterol (LDL-C) is a major risk factor for coronary heart disease (CHD). Many guidelines recommend LDL-C as a primary treatment target, and statins represent the cornerstone of treatment for lipid management. Recently revised guidelines recommend even more intense management of LDL-C, especially in patients at moderate and high risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00317-1DOI Listing
February 2019

Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise.

Am J Cardiovasc Drugs 2019 Apr;19(2):133-171

Ambulatory of Cardiovascular Diseases, Via col. Romey n.10, 91100, Trapani, Italy.

In patients with hypertension, the triad represented by endothelial dysfunction, platelet hyperactivity, and altered fibrinolytic function disturbs the equilibrium between hemostasis and fibrinolysis and translates into a hypercoagulable state, which underlies the risk of thrombotic complications. This article reviews the scientific evidence regarding some biological effects of antihypertensive drugs, which can protect patients from the adverse consequences of hypertensive disease, improving endothelial function, enhancing antioxidant activity, and restoring equilibrium between hemostatic and fibrinolytic factors. These protective effects appear not to be mediated through blood pressure reduction and are not shared by all molecules of the same pharmacological class. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00316-2DOI Listing

How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?

Am J Cardiovasc Drugs 2019 Apr;19(2):107-111

School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.

Bromodomain and extra-terminal (BET) inhibitors, acting via epigenetic mechanisms, have been developed recently as potential new treatments for cancer, including prostate cancer, and inflammatory conditions. Some BET inhibitors, such as RVX-208, also raise high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-1 levels. A recent meta-analysis of three small trials (n = 798) found that RVX-208 protected against major adverse cardiovascular events (MACE), raising the question as to whether this protective effect was an artefact, a chance finding, or mediated by HDL-C, anti-inflammatory pathways, or other factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00315-3DOI Listing

Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.

Am J Cardiovasc Drugs 2019 Jan 25. Epub 2019 Jan 25.

South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia.

The COMPASS trial compared the impact of the selective direct factor Xa inhibitor, rivaroxaban, as monotherapy or in combination with aspirin on major adverse cardiovascular events (MACE) in patients with stable atherosclerotic disease. Patients treated with rivaroxaban 2.5 mg twice daily in combination with aspirin experienced fewer cardiovascular events but more bleeding complications than those who received aspirin monotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00322-4DOI Listing
January 2019

Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.

Am J Cardiovasc Drugs 2019 Apr;19(2):99-105

Interventional Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.

Pulmonary arterial hypertension represents a devastating disease, causing progressive increase of pulmonary vascular resistance leading to right ventricular dysfunction and death. Therapeutic management has rapidly advanced in recent years due to improved understanding of pathophysiology and new drugs have been developed; however, survival remains poor. Oral agents as phosphodiesterase type V inhibitors, the soluble guanylyl cyclase stimulator riociguat, the prostacyclin receptor agonist selexipag and the endothelin receptor antagonists have each achieved evidence-based validation and are recommended for pulmonary arterial hypertension. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00319-zDOI Listing

Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects.

Am J Cardiovasc Drugs 2019 Jan 14. Epub 2019 Jan 14.

GlaxoSmithKline Clinical Unit Cambridge, Addenbrooke's Hospital, Cambridge, UK.

Introduction And Objective: Pulmonary capillary endothelial transient receptor potential vanilloid 4 (TRPV4) channel plays a critical role in mediating the development of cardiogenic pulmonary edema. GSK2798745 is a first-in-class, highly potent, selective, orally active TRPV4 channel blocker being evaluated in a first-time-in-humans study (NCT02119260).

Methods: GSK2798745 was administered in a randomized, placebo-controlled study design to healthy volunteers in three separate cohorts as single escalating doses, with and without food, and as once-daily repeat doses for up to 14 days, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00320-6DOI Listing
January 2019
3 Reads

Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?

Am J Cardiovasc Drugs 2019 Jan 5. Epub 2019 Jan 5.

South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia.

Cholesteryl ester transfer protein (CETP) plays an important role in lipid metabolism and has presented an attractive target for drug development, primarily resting on the hope that CETP inhibition would reduce cardiovascular events through its ability to increase levels of high-density lipoprotein cholesterol (HDL-C). However, clinical development of CETP inhibitors has proven disappointing, with a spectrum of results spanning from evidence of harm, to futility, to only modest benefit in large-scale cardiovascular outcomes trials. A number of additional insights from genomic studies have suggested potential benefits from these agents in specific clinical settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-00323-3DOI Listing
January 2019
1 Read

Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs.

Am J Cardiovasc Drugs 2019 Apr;19(2):113-131

South Australian Health and Medical Research Institute, SAHMRI North Terrace, Adelaide, SA, 5001, Australia.

Epidemiological studies and meta-analyses have consistently suggested the importance of lowering low-density lipoprotein cholesterol (LDL-C) to reduce cardiovascular (CV) events. However, these studies and mechanistic studies using intracoronary imaging modalities have reported patients who continue to experience CV events or disease progression despite optimal LDL-C levels on statins. These findings, including statin intolerance, have highlighted the importance of exploring additional potential therapeutic targets to reduce CV risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0312-1DOI Listing
April 2019
2 Reads

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).

Am J Cardiovasc Drugs 2018 Dec 18. Epub 2018 Dec 18.

Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan.

Introduction: This post hoc subanalysis of the randomized Japanese Primary Prevention Project investigated whether once-daily low-dose aspirin versus no aspirin reduced the risk of cardiovascular events (CVEs) in patients aged ≥ 70 years with atherosclerotic risk factors.

Methods: Patients aged < 70 years (young-old) or ≥ 70 years (old) with hypertension, dyslipidemia, or diabetes participated between 2005 and 2007. Patients were randomized 1:1 to receive 100 mg enteric-coated aspirin once daily or no aspirin plus standard of care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0313-0DOI Listing
December 2018
7 Reads

Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis.

Am J Cardiovasc Drugs 2018 Nov 24. Epub 2018 Nov 24.

Faculty of Pharmacy, Université Laval, Quebec, QC, Canada.

Background: Federal standards authorize the commercialization of generic medicines after bioequivalence versus the brand-name originator has been demonstrated. For drugs with narrow therapeutic indexes, such as warfarin, the accepted difference in bioavailability is ≤ 10%. No systematic pharmacovigilance studies are conducted once generics become available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0309-9DOI Listing
November 2018
13 Reads

DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.

Am J Cardiovasc Drugs 2019 Feb;19(1):75-86

Division of Cardiovascular Surgery, Department of Surgery, Tri Service General Hospital, Taipei, Taiwan, ROC.

Purpose: Current treatment guidelines do not recommend different antiplatelet treatments for patients in different coronary risk categories; nor do they consider ethnic differences in responses to individual drugs.

Objectives: We performed a prospective, single-blind, randomized, comparative study of Taiwanese patients with stable angina and scheduled stent implantation for intermediate-to-highly complex coronary lesions and compared the platelet reactivity unit (PRU) levels and 24-month outcomes of groups receiving three different antiplatelet treatments.

Methods: Patients (N = 334) were randomized into three treatment groups (aspirin + clopidogrel, aspirin + ticagrelor, or aspirin + clopidogrel + cilostazol) for 6 months of treatment and were then switched to aspirin only. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0302-3DOI Listing
February 2019
4 Reads

Long-Term Effects of Bosentan on Cardiovascular Events in Hispanic Patients with Intermittent Claudication: Four-Year Follow-up of the CLAU Trial : The CLAU Randomized Trial Long-Term Outcome.

Am J Cardiovasc Drugs 2019 Apr;19(2):203-209

Angiology and Vascular Surgery Department, Getafe University Hospital, Ctra. Toledo km 12.300, Getafe, 28905, Madrid, Spain.

Introduction: The Clinical and Endothelial Function Assessment after Endothelin Receptor Antagonist (CLAU) trial demonstrated the effect of bosentan on the endothelial function, inflammatory status and claudication distance in Hispanic patients with incipient peripheral arterial disease (PAD). Our aim was to assess the protective effect on cardiovascular events of bosentan versus conventional anti-atherosclerosis therapy.

Methods: CLAU included 56 patients with intermittent claudication, randomized 1:1 to receive bosentan for 12 weeks (n = 27) or placebo (n = 29), associating the best medical treatment. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40256-018-0307-y
Publisher Site
http://dx.doi.org/10.1007/s40256-018-0307-yDOI Listing
April 2019
8 Reads

Optimal Medical Therapy Prescribing Patterns and Disparities Identified in Patients with Acute Coronary Syndromes at an Academic Medical Center in an Area with High Coronary Heart Disease-Related Mortality.

Am J Cardiovasc Drugs 2019 Apr;19(2):185-193

TRC Healthcare, Pharmacist's Letter, Oklahoma City, OK, USA.

Background: Coronary heart disease (CHD)-related mortality is high in the southern United States. A five-drug pharmacotherapy regimen for acute coronary syndromes (ACS), defined as optimal medical therapy (OMT), can decrease CHD-related mortality. Studies have indicated that OMT is prescribed 50-60% of the time. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40256-018-0308-x
Publisher Site
http://dx.doi.org/10.1007/s40256-018-0308-xDOI Listing
April 2019
9 Reads

Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients.

Am J Cardiovasc Drugs 2019 Apr;19(2):195-201

Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos, Lebanon.

Background: Non-vitamin K oral anticoagulants (NOACs) have emerged as an attractive alternative to vitamin K antagonists for various thromboembolic indications. However, prescribed NOAC doses are often inconsistent with drug labeling and prescribers might not consider the potential risks associated with concomitant use of other drugs, which can compromise NOACs' safety and effectiveness.

Methods: A retrospective chart review was conducted in a tertiary care center in USA over a 4-month period. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40256-018-0310-3
Publisher Site
http://dx.doi.org/10.1007/s40256-018-0310-3DOI Listing
April 2019
11 Reads

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine.

Am J Cardiovasc Drugs 2019 Apr;19(2):173-183

Sorbonne Université, ACTION Study Group, Hôpital Pitié-Salpêtrière (AP-HP), 47 boul de l'Hôpital, 75013, Paris, France.

Background: Morphine adversely impacts the action of oral adenosine diphosphate (ADP)-receptor blockers in ST-segment elevation myocardial infarction (STEMI) patients, and is possibly associated with differing patient characteristics. This retrospective analysis investigated whether interaction between morphine use and pre-percutaneous coronary intervention (pre-PCI) ST-segment elevation resolution in STEMI patients in the ATLANTIC study was associated with differences in patient characteristics and management.

Methods: ATLANTIC was an international, multicenter, randomized study of treatment in the acute ambulance/hospital setting where STEMI patients received ticagrelor 180 mg ± morphine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0305-0DOI Listing
April 2019
21 Reads

Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.

Am J Cardiovasc Drugs 2019 Feb;19(1):1-10

Département de Cardiologie, Hôpital Arnaud de Villeneuve, CHU de Montpellier, UFR de Médecine, Université Montpellier 1, 371, avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades. According to recent and promising studies, sacubitril/valsartan (SV) might be efficient in alternative indications in the area of HF with preserved left ventricular ejection fraction, chronic kidney disease, and so on. This review briefly summarizes these promising therapeutic options regarding SV and the potential limits and pitfalls for its use in routine practice (due to cognitive uncertainties). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0306-zDOI Listing
February 2019

Statin Use and Gastrointestinal Hemorrhage: A Large Retrospective Cohort Study.

Am J Cardiovasc Drugs 2019 Feb;19(1):65-74

College of Pharmacy, University of Kentucky, Lexington, KY, USA.

Background: Nearly 70% of Americans with cardiovascular disease use statins, which have documented bleeding effects independent of their cholesterol-lowering activities. However, the literature is conflicting regarding the association between statin use and gastrointestinal hemorrhage.

Objectives: The aim of this study was to investigate the risk of gastrointestinal hemorrhage in statin users. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0301-4DOI Listing
February 2019
15 Reads

Short-Term Effects of Tolvaptan in Tricuspid Insufficiency Combined with Left Heart Valve Replacement-Caused Volume-Overload Patients: Results of a Prospective Pilot Study.

Am J Cardiovasc Drugs 2019 Apr;19(2):211-218

Department of Emergency, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200336, China.

Objectives: Our objective was to explore the effects of tolvaptan as a new therapeutic approach in patients with right heart failure with tricuspid insufficiency (TI).

Methods: This prospective, multicenter, non-randomized controlled pilot study enrolled patients (N = 40) with TI from the Shanghai Chest Hospital and Shanghai Tongren Hospital who fulfilled inclusion criteria between March 2015 and June 2016. Participants were assigned to receive either tolvaptan combined with torasemide (n = 20) or torasemide monotherapy (n = 20; control group). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40256-018-0304-1
Publisher Site
http://dx.doi.org/10.1007/s40256-018-0304-1DOI Listing
April 2019
9 Reads

A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels.

Am J Cardiovasc Drugs 2019 Feb;19(1):87-97

Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing, 100037, China.

Background: Lipoprotein (a) [Lp(a)] is an atherogenic lipoprotein. While no effective therapy for Lp(a) is currently available, recently, several pooled analyses with small sample sizes have suggested that proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9-mAbs) could reduce circulating Lp(a) levels. This meta-analysis was performed to comprehensively investigate the efficacy of PCSK9-mAbs with respect to serum Lp(a) concentrations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0303-2DOI Listing
February 2019
9 Reads

Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.

Am J Cardiovasc Drugs 2019 Feb;19(1):59-64

Department of Pharmacy Practice, Lebanese American University, Byblos, Lebanon.

Background: Idarucizumab is used to reverse the effects of dabigatran. Information on the use of idarucizumab in the clinical setting remains very limited.

Objective: The objective of this study was to describe clinical experience with idarucizumab in a large medical teaching center in the USA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0300-5DOI Listing
February 2019
4 Reads

Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials.

Am J Cardiovasc Drugs 2019 Feb;19(1):37-47

Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.

Background: There are conflicting published data on non-vitamin K antagonist oral anticoagulants (NOACs), with varying evidence of benefit or harm in acute coronary syndrome (ACS) and non-ACS cohorts. To explore the efficacy and safety of NOAC use in patients with ischemic heart disease (IHD), we conducted a meta-analysis of phase III randomized controlled trials (RCTs).

Methods: We systematically searched the Cochrane Library, PubMed, and Embase databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0299-7DOI Listing
February 2019
4 Reads

The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.

Am J Cardiovasc Drugs 2019 Feb;19(1):49-57

Vascular Research Centre, Heart Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia.

Background: Apabetalone is a selective bromodomain and extra-terminal (BET) inhibitor which modulates lipid and inflammatory pathways implicated in atherosclerosis. The impact of apabetalone on attenuated coronary atherosclerotic plaque (AP), a measure of vulnerability, is unknown.

Methods: The ApoA-1 Synthesis Stimulation and intravascular Ultrasound for coronary atheroma Regression Evaluation (ASSURE; NCT01067820) study employed serial intravascular ultrasound (IVUS) measures of coronary atheroma in 281 patients treated with apabetalone or placebo for 26 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0298-8DOI Listing
February 2019
30 Reads

Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin.

Am J Cardiovasc Drugs 2018 Dec;18(6):503-511

Sorbonne Université-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), 47-83 bld de l'Hôpital, 75013, Paris, France.

Background: The aim was to compare the peri-procedural biomarkers of coagulation and platelet activation in patients randomly allocated to intravenous enoxaparin or unfractionated heparin (UFH) in the ATOLL randomized trial (NCT00718471).

Methods And Results: A total of 129 patients (n = 58 enoxaparin and n = 71 UFH) admitted for ST-segment elevation myocardial infarction (STEMI) treated by percutaneous coronary intervention (PCI) were included in this substudy of the ATOLL trial. Activated partial thromboplastin time ratio, anti-Xa activity, von Willebrand factor antigen, prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin complex (TAT), tissue factor pathway inhibitor and soluble CD40 ligand were measured at sheath insertion (T1) and at the end of the PCI (T2) and correlated with 1-month clinical outcomes. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40256-018-0294-z
Publisher Site
http://dx.doi.org/10.1007/s40256-018-0294-zDOI Listing
December 2018
16 Reads
2.203 Impact Factor

FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.

Am J Cardiovasc Drugs 2019 02;19(1):11-20

Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Room #4128, Silver Spring, MD, USA.

Distributive shock is a subset of shock marked by decreased systemic vascular resistance, organ hypoperfusion and altered oxygen extraction. Despite the use of intravenous fluids and either higher dose of catecholamines or other additional exogenous vasopressors to maintain blood pressure in the target range, the rate of mortality remains higher in patients with septic shock. Therefore, there is clearly an unmet need for additional safe and effective treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0297-9DOI Listing
February 2019
28 Reads

Healthcare Utilization and Expenditures in Working-Age Adults with Atrial Fibrillation: The Effect of Switching from Warfarin to Non-Vitamin K Oral Anticoagulants.

Am J Cardiovasc Drugs 2018 Dec;18(6):513-520

Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA.

Objective: Our objective was to evaluate the association between switching from warfarin to non-vitamin K oral anticoagulants (NOACs) and potential drug-drug interactions (DDIs), healthcare utilization, and expenditures in working-age adults with atrial fibrillation (AF).

Methods: We conducted a retrospective cohort study using data from 2010 to 2015 for patients who switched from warfarin to NOACs (switchers) and those who continued to receive warfarin (non-switchers). We identified medications known or suspected to have clinically significant interactions with NOACs or warfarin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0296-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428195PMC
December 2018
16 Reads

Early and Late Stent Thrombosis in Patients with Versus Without Diabetes Mellitus Following Percutaneous Coronary Intervention with Drug-Eluting Stents: A Systematic Review and Meta-Analysis.

Am J Cardiovasc Drugs 2018 Dec;18(6):483-492

Department of Cardiology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, Guangxi, People's Republic of China.

Background: Nowadays, drug-eluting stents (DES) are most commonly used compared with bare metal stents (BMS) since the former are associated with significantly lower rates of revascularization following percutaneous coronary intervention (PCI). However, unpredictable in-stent thrombosis is a major concern with DES, especially in patients with diabetes mellitus.

Objective: In this analysis, we aimed to systematically compare early and late stent thrombosis in patients with versus without diabetes mellitus following PCI with DES. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0295-yDOI Listing
December 2018
16 Reads

Patients' Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis.

Am J Cardiovasc Drugs 2018 Dec;18(6):493-502

Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, P.O. Box 217, 7500 AE, Enschede, The Netherlands.

Introduction: Effectiveness of oral anticoagulants (OACs) is critically dependent on patients' adherence to intake regimens. We studied the relative impact of attributes related to effectiveness, safety, convenience, and costs on the value of OAC therapy from the perspective of patients with non-valvular atrial fibrillation.

Methods: Four attributes were identified by literature review and expert interviews: effectiveness (risk of ischemic stroke), safety (risk of major bleeding, minor bleeding, gastrointestinal complaints), convenience (intake frequency, diet restrictions, international normalized ratio [INR] blood monitoring, pill type/intake instructions), and out-of-pocket costs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40256-018-0293-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267541PMC
December 2018
34 Reads